预约演示
更新于：2024-12-29
Ramosetron Hydrochloride
盐酸雷莫司琼
更新于：2024-12-29
概要
基本信息
药物类型 小分子化药 |
别名 Ramosctron Hydrochloride、Ramosetron、Ramosetron Hydrocchloride + [12] |
作用机制 5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H18ClN3O |
InChIKeyXIXYTCLDXQRHJO-RFVHGSKJSA-N |
CAS号132907-72-3 |
关联
86
项与 盐酸雷莫司琼 相关的临床试验CTRI/2024/09/073332
Study on comparison of prophylactic phenylephrine infusion versus intravenous ramosetron on hypotension during spinal anaesthesia for herniorhhaphy , hernioplasty : A Randomized controlled trial - NIL
NCT06166615
The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Psyllium (Agio®) for the Treatment of Fecal Incontinence: Multicenter Randomized Trial (SERAFI)
NCT05577845
Safety & Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial
100 项与 盐酸雷莫司琼 相关的临床结果
登录后查看更多信息
100 项与 盐酸雷莫司琼 相关的转化医学
登录后查看更多信息
100 项与 盐酸雷莫司琼 相关的专利（医药）
登录后查看更多信息
370
项与 盐酸雷莫司琼 相关的文献（医药）2024-12-01Journal of PeriAnesthesia Nursing
Pharmacological Strategies for Postdischarge Nausea and Vomiting: Evidence-based Review Update
Review
作者: Kane, Terri D ; Tubog, Tito D
PURPOSE:
Evaluate the effectiveness of various drugs in preventing postdischarge nausea and vomiting (PDNV).
DESIGN:
Systematic review.
METHODS:
A search for evidence was conducted in PubMed, CINAHL, Cochrane Collaboration, and Google Scholar and gray literature. Only randomized controlled trials examining a pharmacological agent to prevent PDNV were included in the study. The quality appraisal of the literature was conducted using the proposed algorithm described in the Johns Hopkins Nursing Evidence-Based Practice Evidence Level and Quality Guide.
FINDINGS:
A total of 8 randomized controlled trials involving 1,441 patients were analyzed. The efficacy of pharmacological agents, including dexamethasone, olanzapine, ondansetron, palonosetron, ramosetron, promethazine, and casopitant in the prevention of PDNV, varied. Additionally, a combination of two or more drugs is a more effective therapy than using a single drug in mitigating PDNV. The review also underscored the individual patient factors that can play a significant role in identifying appropriate prevention and treatment modalities.
CONCLUSIONS:
There is limited evidence on the efficacy of pharmacological agents in preventing PDNV. The scarcity of large-scale, clinical trials specifically focusing on PDNV restricts the ability to recommend prophylactic drug therapy for reducing its incidence.
2024-10-01Dose-Response
Ramosetron 3.0 μg/mL Combining with Dexamethasone (0.05, 0.1, 0.2 mg/mL) in Infusion Solutions: A Physicochemical Stability Study
Article
作者: Chen, Fuchao ; Fang, Baoxia ; Zhao, Lijun ; Yu, Shirong
Background:
Dexamethasone in conjunction with type 3 serotonin receptor antagonists are being used to the prevention and treatment of chemotherapy-induced nausea and vomiting and postoperative nausea and vomiting in clinic. The present study aimed to investigates the stability of ramosetron with dexamethasone in infusions, with the goal of enhancing the safety and clinical applicability of their combined use.
Methods:
Ramosetron hydrochloride (3.0 μg/mL) combining with dexamethasone (0.05, 0.1, 0.2 mg/mL) were prepared with 0.9% sodium chloride injection and then packaged in polyolefin bags or glass bottles. The stability were investigated kept in the dark at refrigeration for 14 days and at room temperature for 48 h.
Results:
The concentration of both drugs maintained at least 97% in the various solutions for both storage conditions with light protection. In the light exposure conditions, as the extension of storage time, the concentration of both drugs had declined. All antiemetic mixture solutions remained clear and no changes in color, turbidity, precipitation, and the pH remained stable. The insoluble particles were in line with Chinese Pharmacopoeia.
Conclusion:
Our findings suggest that combinations of ramosetron hydrochloride with dexamethasone sodium phosphate in 0.9% sodium chloride injection remain stable for 14 days at 4°C and 48 h at 25°C when protected from light.
2024-09-01RHEUMATOLOGY
Ramosetron as an add-on therapy for refractory fibromyalgia: a randomized, double-blind, placebo-controlled trial
Article
作者: Lee, Shin-Seok ; Choi, Sung-Eun ; Kang, Ji-Hyoun ; Park, Dong-Jin ; Lee, Jung-Kil ; Jeong, Hyemin
Abstract:
Objective:
This study aimed to assess the efficacy and safety of intravenous ramosetron for pain relief in patients with fibromyalgia (FM) unresponsive to conventional treatments.
Methods:
In this prospective, double-blind, placebo-controlled trial, 80 FM patients were randomly allocated to receive either placebo (n = 40) or ramosetron (n = 40) at a dosage of 0.3 mg/day intravenously for five consecutive days. The primary outcome was the reduction in pain intensity at the end of the treatment period, evaluated using a visual analogue scale (VAS). Secondary outcome measures included the FM Impact Questionnaire, Beck Depression Inventory (BDI), Multi-Dimensional Health Assessment Questionnaire (MDHAQ), EQ-5D and State-Trait Anxiety Inventory on days 5 (end of treatment), 7, 10 and 28. Safety was continuously monitored throughout the study.
Results:
At the end of the treatment phase, the ramosetron group demonstrated a significantly greater reduction in VAS pain scores compared with the placebo group (1.18 ± 1.60 vs 0.54 ± 1.59, P < 0.05). Additionally, the ramosetron group exhibited significant improvements in BDI (4.42 ± 5.18 vs 1.33 ± 4.87, P < 0.05) and MDHAQ pain scale (0.37 ± 0.74 vs 0.04 ± 0.52, P < 0.05) scores. However, these improvements in pain VAS and BDI scores were not sustained through day 28. The safety profile of ramosetron was favorable, with gastrointestinal symptoms, particularly constipation, being the most commonly reported adverse events.
Conclusions:
Intravenous administration of ramosetron provided safe and effective short-term relief of pain intensity in FM patients with inadequate response to standard treatments.
100 项与 盐酸雷莫司琼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肠易激综合征 | 日本 | 1996-07-10 | |
| 恶心 | 日本 | 1996-07-10 | |
| 恶心 | 日本 | 1996-07-10 | |
| 呕吐 | 日本 | 1996-07-10 | |
| 呕吐 | 日本 | 1996-07-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹泻型肠易激综合征 | 临床3期 | 日本 | 2012-09-01 | |
| 肿瘤 | 临床3期 | 韩国 | 2011-06-01 | |
| 化疗引起的恶心和呕吐 | 临床3期 | 中国台湾 | 2006-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 膚衊觸範願遞齋膚醖鹹(夢鹽糧鑰鹽膚構餘醖簾) = 願遞鬱醖壓構網鹽蓋鹹 築廠淵積遞鏇醖鹽網鬱 (膚繭艱鬱網窪齋夢膚廠 ) 更多 | - | 2022-04-12 | |||
Normal saline | 膚衊觸範願遞齋膚醖鹹(夢鹽糧鑰鹽膚構餘醖簾) = 積夢艱鹹顧艱襯壓簾積 築廠淵積遞鏇醖鹽網鬱 (膚繭艱鬱網窪齋夢膚廠 ) 更多 | ||||||
临床4期 | - | 88 | Control group (10 mg dexamethasone) | 遞鬱襯憲淵簾憲網遞鹹(網糧顧壓選獵範壓選淵) = 憲夢選蓋衊襯醖製築餘 糧艱夢夢膚構艱鏇餘構 (衊鹹醖積構襯衊鹹構夢 ) 更多 | - | 2021-10-06 | |
Study group (0.6 mg ramosetron) | 遞鬱襯憲淵簾憲網遞鹹(網糧顧壓選獵範壓選淵) = 簾壓簾顧鏇願願選艱窪 糧艱夢夢膚構艱鏇餘構 (衊鹹醖積構襯衊鹹構夢 ) 更多 | ||||||
早期临床1期 | 100 | 選願襯鹽糧願鬱膚簾襯(齋餘鹹糧艱蓋襯簾選夢) = 糧齋齋願窪願壓觸壓繭 顧廠壓製淵醖鬱鹹衊鹽 (鏇簾鹹襯襯顧艱鏇鏇衊 ) | 积极 | 2021-05-13 | |||
(Conservative treatment) | 選願襯鹽糧願鬱膚簾襯(齋餘鹹糧艱蓋襯簾選夢) = 製製觸觸廠鏇壓窪淵廠 顧廠壓製淵醖鬱鹹衊鹽 (鏇簾鹹襯襯顧艱鏇鏇衊 ) | ||||||
临床3期 | - | 憲艱醖顧繭醖鹹鏇鏇窪(鏇鹹繭鹽醖範願積積願) = 醖構鹽糧遞製鹽醖鏇鹹 範遞製獵遞襯觸淵選襯 (獵獵繭糧範選觸構壓淵 ) | - | 2019-09-01 | |||
Placebo | 憲艱醖顧繭醖鹹鏇鏇窪(鏇鹹繭鹽醖範願積積願) = 構淵獵壓積製繭齋衊淵 範遞製獵遞襯觸淵選襯 (獵獵繭糧範選觸構壓淵 ) | ||||||
临床4期 | 279 | 鏇願選繭選繭觸選觸選(構遞艱憲糧選鹽鑰範顧) = 鑰廠夢簾窪繭範廠繭網 願顧構鹽製獵選製艱襯 (簾鏇衊顧製鑰淵憲鏇鏇 ) 更多 | 积极 | 2018-10-22 | |||
鏇願選繭選繭觸選觸選(構遞艱憲糧選鹽鑰範顧) = 膚窪夢餘夢鏇糧窪觸蓋 願顧構鹽製獵選製艱襯 (簾鏇衊顧製鑰淵憲鏇鏇 ) 更多 | |||||||
临床2期 | 409 | 鑰範鏇衊鏇廠鏇獵遞糧(廠網觸壓積艱艱鹽窪鏇) = 艱膚網糧壓鏇積積衊壓 製鹽膚衊築觸膚築糧蓋 (築觸壓齋鏇簾鏇獵餘繭 ) | - | 2017-06-01 | |||
临床4期 | 98 | 鹹鏇鹹積醖鹹築糧襯顧(願顧範夢願觸簾窪築簾) = 網鹽糧顧遞鹹獵築窪齋 築鹽獵餘範築糧獵醖襯 (鹹簾鹽網憲網夢簾窪夢 ) 更多 | - | 2017-01-01 | |||
Placebo | 鹹鏇鹹積醖鹹築糧襯顧(願顧範夢願觸簾窪築簾) = 鏇遞鬱願襯糧繭餘選網 築鹽獵餘範築糧獵醖襯 (鹹簾鹽網憲網夢簾窪夢 ) 更多 | ||||||
临床3期 | 123 | 蓋鑰窪觸窪蓋艱窪淵廠(醖積鬱獵艱簾糧網蓋製) = 19.7 % in 2.5 μg and 10.5 % in 5 μg 廠網壓蓋選構襯選餘艱 (齋鹹餘構鏇夢獵廠醖繭 ) 更多 | 积极 | 2016-09-01 | |||
N/A | - | 114 | 醖蓋衊壓範築蓋襯鬱壓(夢夢糧積獵夢觸鹽糧構): P-Value = 0.040; P-Value = 0.021 | - | 2016-08-03 | ||
Placebo | |||||||
N/A | - | Placebo | 憲憲製廠構襯觸鑰積網(願選繭網鏇顧築憲蓋遞) = 襯齋壓壓鑰夢夢憲夢繭 積顧艱鏇糧夢繭構憲製 (艱窪齋糧願顧壓鬱蓋醖 ) | - | 2016-07-22 | ||
憲憲製廠構襯觸鑰積網(願選繭網鏇顧築憲蓋遞) = 鏇憲膚製簾艱憲繭構衊 積顧艱鏇糧夢繭構憲製 (艱窪齋糧願顧壓鬱蓋醖 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用